Roles of β-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders
Handbook of Experimental Pharmacology · 2024
DOI: 10.1007/164_2024_720 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Handbook of Experimental Pharmacology, 2024. Verfasst von Yee Weng Wong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Cha…. Hauptthemen laut MEDLINE: Heart Failure, Receptors, Adrenergic, beta, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 230 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
β-Adrenoceptors (β-ARs) provide an important therapeutic target for the treatment of cardiovascular disease. Three β-ARs, β1-AR, β2-AR, β3-AR are localized to the human heart. Activation of β1-AR and β2-ARs increases heart rate, force of contraction (inotropy) and consequently cardiac output to meet physiological demand. However, in disease, chronic over-activation of β1-AR is responsible for the progression of disease (e.g. heart failure) mediated by pathological hypertrophy, adverse remodelling and premature cell death. Furthermore, activation of β1-AR is critical in the pathogenesis of cardiac arrhythmias while activation of β2-AR directly influences blood pressure haemostasis. There is an increasing awareness of the contribution of β2-AR in cardiovascular disease, particularly arrhythmia generation. All β-blockers used therapeutically to treat cardiovascular disease block β1-AR with variable blockade of β2-AR depending on relative affinity for β1-AR vs β2-AR. Since the introduction of β-blockers into clinical practice in 1965, β-blockers with different properties have been trialled, used and evaluated, leading to better understanding of their therapeutic effects and tolerability in various cardiovascular conditions. β-Blockers with the property of intrinsic sympathomimetic activity (ISA), i.e. β-blockers that also activate the receptor, were used in the past for post-treatment of myocardial infarction and had limited use in heart failure. The β-blocker carvedilol continues to intrigue due to numerous properties that differentiate it from other β-blockers and is used successfully in the treatment of heart failure. The discovery of β3-AR in human heart created interest in the role of β3-AR in heart failure but has not resulted in therapeutics at this stage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Chermside, QLD, Australia.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Cardiology, The Prince Charles Hospital, Chermside, QLD, Australia.
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
- Cardiovascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Chermside, QLD, Australia. p.molenaar@uq.edu.au.
- Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. p.molenaar@uq.edu.au.
Zitieren
APA
Wong, Y. W., Haqqani, H., & Molenaar, P. (2024). Roles of β-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders. Handbook of Experimental Pharmacology. https://doi.org/10.1007/164_2024_720
Vancouver
Wong YW, Haqqani H, Molenaar P. Roles of β-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders. Handbook of Experimental Pharmacology. 2024. doi:10.1007/164_2024_720
BibTeX
@article{Wong2024,
author = {Wong, Yee Weng and Haqqani, Haris and Molenaar, Peter},
title = {Roles of β-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders},
journal = {Handbook of Experimental Pharmacology},
year = {2024},
doi = {10.1007/164_2024_720}
}
EUVIMED